GRM1 and autoimmune disease: Fifty percent of patients with malignancy had it within 5 years of the autoimmune cerebellitis or encephalitis onset; 16.7% (n = 6/36) of patients were diagnosed with an autoimmune disease other than that involving mGluR1 antibodies.